Loading...
MEGA logo

Mega Lifesciences Public Company LimitedSET:MEGA Stock Report

Market Cap ฿29.2b
Share Price
฿33.50
n/a
1Y-0.7%
7D3.9%
Portfolio Value
​
View

Mega Lifesciences Public Company Limited

SET:MEGA Stock Report

Market Cap: ฿29.2b

Mega Lifesciences (MEGA) Stock Overview

Manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. More details

MEGA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance6/6
Financial Health6/6
Dividends4/6

Rewards

Trading at 16.9% below our estimate of its fair value

Earnings are forecast to grow 9.96% per year

Earnings grew by 6.9% over the past year

Risk Analysis

Unstable dividend track record


MEGA Community Fair Values

Create Narrative

See what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.

MEGA logo
Mega Lifesciences

Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets

Key Takeaways Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth. Diversified product pipeline and focus on preventive healthcare align with rising demand, driving consistent earnings momentum and unlocking higher value per unit.
View narrative
฿34.58
FV
3.1% undervalued intrinsic discount
4.56%
Revenue growth p.a.
24
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
MEGA logo
Mega Lifesciences

Myanmar Scrutiny And FX Risks Will Dampen Prospects With Upside

Key Takeaways Reliance on traditional products and lack of innovation risk shrinking market relevance and long-term growth opportunities amid evolving consumer preferences. Regulatory, geopolitical, and competitive pressures are likely to drive up costs, increase earnings volatility, and compress margins, challenging overall profitability.
View narrative
฿26
FV
28.8% overvalued intrinsic discount
0.84%
Revenue growth p.a.
3
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
MEGA logo
Mega Lifesciences

Aging Populations And Emerging Markets Will Drive Wellness Demand

Key Takeaways Accelerated manufacturing expansion, robust product pipeline, and localization strategies position Mega Lifesciences for outperformance in topline growth and margin resilience. Early focus on prevention-oriented brands and proactive market adaptation may lead to dominant status and sustained earnings growth amid evolving health trends.
View narrative
฿39
FV
14.1% undervalued intrinsic discount
6.83%
Revenue growth p.a.
4
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
View Stock Community

Mega Lifesciences Public Company Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Mega Lifesciences
Historical stock prices
Current Share Price฿33.50
52 Week High฿35.50
52 Week Low฿24.30
Beta0.23
1 Month Change0%
3 Month Change6.35%
1 Year Change-0.74%
3 Year Change-32.32%
5 Year Change-14.10%
Change since IPO57.28%

Recent News & Updates

Recent updates

User avatar

Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets

Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth.

Shareholder Returns

MEGATH PharmaceuticalsTH Market
7D3.9%-1.5%-0.4%
1Y-0.7%12.1%-7.6%

Return vs Industry: MEGA underperformed the TH Pharmaceuticals industry which returned 11.1% over the past year.

Return vs Market: MEGA exceeded the TH Market which returned -8.8% over the past year.

Price Volatility

Is MEGA's price volatile compared to industry and market?
MEGA volatility
MEGA Average Weekly Movement4.6%
Pharmaceuticals Industry Average Movement4.5%
Market Average Movement3.9%
10% most volatile stocks in TH Market8.0%
10% least volatile stocks in TH Market1.8%

Stable Share Price: MEGA has not had significant price volatility in the past 3 months compared to the TH market.

Volatility Over Time: MEGA's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1982n/aVivek Dhawanwww.megawecare.com

Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provides various medicines for allergies; blood circulation and memory; bone and joint; liver and digestive; diabetics; eyes, heart, and skin care; pain, sleeping, well-being, herbal, and cough and colds; and vitamins, probiotics, medical and sports nutrition, as well as kids’, men’s, and women’s care products.

Mega Lifesciences Public Company Limited Fundamentals Summary

How do Mega Lifesciences's earnings and revenue compare to its market cap?
MEGA fundamental statistics
Market cap฿29.21b
Earnings (TTM)฿1.97b
Revenue (TTM)฿14.19b
14.8x
P/E Ratio
2.1x
P/S Ratio

Is MEGA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MEGA income statement (TTM)
Revenue฿14.19b
Cost of Revenue฿6.76b
Gross Profit฿7.44b
Other Expenses฿5.46b
Earnings฿1.97b

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)2.26
Gross Margin52.40%
Net Profit Margin13.91%
Debt/Equity Ratio4.5%

How did MEGA perform over the long term?

See historical performance and comparison

Dividends

4.8%
Current Dividend Yield
71%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/01 16:56
End of Day Share Price 2025/12/30 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mega Lifesciences Public Company Limited is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Graham PriceCGS International
Thanapol JiratanakijCGS International
Chanpen SirithanarattanakulDBS Bank Ltd